Devita, Hellman, and Rosenberg's Cancer

LWBK1006-42 LWW-Govindan-Review December 12, 2011 20:38

528 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 42.15. The risk for graft failure is increased by all of the following, EXCEPT:

A. T-cell depletion of the product

B. Less than 1×106 CD34+cells/kg recipient body weight

C. Matched sibling SCT

D. Umbilical cord blood transplant

Question 42.16. In which setting is the risk of CMV reactivation the highest after allogeneic

HCT?

A. CMV-positive donor to a CMV-negative recipient

B. CMV-negative donor to a CMV-positive recipient

C. CMV-negative donor to a CMV-negative recipient

D. CMV-positive donor to a CMV-positive recipient

Question 42.17. Peripheral blood mobilized stem cell allografts, compared with bone mar-

row, are associated with which of the following:

A. Shorter period of neutropenia

B. Shorter period to platelet recovery

C. Equivalent T-cell numbers

D. Equivalent incidence of acute GVHD

E. A, B, and D

Question 42.18. For which of the following patients with an HLA-matched donor is allo-

geneic stem cell transplantation MOST appropriate?

A. A 35-year-old man with AML with inversion 16 in CR1 after 7+ 3

B. A 40-year-old woman with AML and complex cytogenetics in first

clinical remission (CR)

C. A 48-year-old woman with diffuse large B-cell lymphoma with

chemosensitive relapse after initial remission of 18 months

D. A 55-year-old man with Rai stage III chronic lymphocytic leukemia

(CLL) in first remission

Question 42.19. All of the following are potential complications of donor lymphocyte

infusion (DLI), EXCEPT:

A. Bone marrow aplasia

B. GVHD flare

C. VOD

D. A and B

Question 42.20. Common manifestations of CMV reactivation after allogeneic SCT

include each of the following, EXCEPT:

A. Pneumonitis

B. Colitis

C. Retinitis

D. Bone marrow suppression